GxP Applications

  • The systems include Octet CFR software and ForteBio’s FB server features for secure and traceable electronic record keeping
  • Optional IQ/OQ/PQ packages ensure that Octet systems are qualified and operate as intended
  • Support services in software and biosensor validation are provided

Octet solutions for lot release

Overview for Biologics GxP Applications

Regulatory requirements necessitate that biologics drug products be QC tested using methods that are robust and have been appropriately developed, qualified, and validated under GMP conditions. Among these assays, titer measurement for potency assessment and ligand binding kinetics assays are increasingly being used for biological products' lot release. Drug developers are constantly in search of analytical technologies with robust features that are easy to use and adaptable in QC and manufacturing.

Fc receptor binding assays on the Octet system

The safety and efficacy of a therapeutic monoclonal antibody can be greatly impacted by its ability to bind to both the target and to the FcγR. Antibodies are often selected based on their binding properties to FcγRs. They are sometimes engineered to achieve desired FcγRs binding properties. As a result, the assessment of binding affinities of these antibodies to FcγRs is an integral part of biotherapeutic development processes.

 
  • Octet systems offer high throughput and sensitive methods for Fc receptor binding analysis
  • A variety of biosensor surfaces are available and allow for flexibility and rapid optimization of assay format
Ligand Binding Assays

Ligand binding potency assays on the Octet platform

Reproducible and accurate relative ligand binding potency methods can be developed using analytical technologies. These methods can be used to asses lot-to-lot variability by monitoring either the kinetics of binding or by comparing affinity constants. They can also be used to determine the stability of the different lots of the drug, hence the method has to indicate stability. Due to their ease of use and fast time to results, real-time label-free analytical techniques are increasingly becoming attractive for the development of methods for assessing the potency of drug candidates.

 
  • Readily accommodates the use of DOEs to rapidly develop robust potency measurement methods
  • Develops relative affinity constant or response signals comparability studies for potency measurements

Titer determination on the Octet platform

Titer and protein concentration determination is a critical process in the development of biologics drug molecules. The active protein concentration can be used to determine the potency of the drug molecule. While ELISA and especially HPLC are commonplace techniques for titer and protein concentration determination, techniques that are more robust to cell culture and media are especially desirable as they can be easily adopted in both upstream and downstream processes during the development of the drug molecule.

 
  • A full plate (96 samples) of IgG titer can be analyzed in as little as two minutes
  • Sample plate format allows for the use of crude and non-purified samples
  • Automation capable Octet HTX and Red 384 allow for walkaway high throughput analysis

Resources of GxP Applications

Application Note Analysis of Fc-gamma Receptor-IgG Interactions on the Octet Platform

Fc gamma receptors (FcγRs) are membrane glycoproteins with affinity for the Fc region of immunoglobulin G (IgG). FcγRs expressed on the surface of immune effector cells play a key role in initiating Fc effector functions such as antibody-mediated cell-dependent cytotoxicity (ADCC)1, which is a major mechanism of action of therapeutic monoclonal antibodies

Read more

Application Note Analysis of FcRn-Antibody Interactions on the Octet Platform

The Fc region of human IgG contributes to a number of beneficial biological and pharmacological characteristics of therapeutic antibodies.

Read more

Application Note Octet Potency Assay: Development, Qualification and Validation Strategies

Kinetic analysis of biomolecular interactions is critical during drug discovery and development. The affinity of an interaction directly affects the dose required for a biopharmaceutical to be effective.

Read more

Application Note Enhancing Efficiency and Economics in Process Development and Manufacturing of Biotherapeutics

Analytical techniques that measure protein quantity and quality are used in nearly all stages of research, process development and manufacturing of biotherapeutics. UV spectroscopy, ELISA and HPLC have been in use for decades for protein quantitation in physiologi- cal and process samples, and continue to be the workhorses despite their many limitations. Read more

Application Note Validated Quantitation and Activity Assay of Antibody Fragment Molecule (Fab) for Process Development and Quality Control

The group was able to develop a working Fab activity assay on the Octet RED system in less than a week. Relative to the overnight incubation and four-hour assay time of their ELISA protocol, the Octet assay provided an analysis time of only one hour per 96-well microplate, including sample preparation time. This Octet assay was used to monitor Fab activity for all process development studies.

Read more

Flyer Quality control of biotherapeutics using Octet systems

Bio-Layer Interferometry (BLI) has been rapidly adopted as an important analytical tool in laboratories that work with biological molecules, either as drug products, vaccines, or diagnostic reagents.

Read more

White Paper Octet platform: a complete solution for lot release and in-process testing of biologics in GxP laboratories

Bio-Layer Interferometry (BLI) is an optical analytical technique that analyzes the interference pattern of white light reflected from two surfaces: a layer of immobilized protein on the biosensor tip and an internal reference layer (Figure 1A). Any change in the number of molecules bound to the biosensor tip causes a shift in the interference pattern that can be measured in real time (Figure 1A and 1B). The binding between a ligand immobilized on the biosensor surface and an analyte in solution produces an increase in optical thickness measured as a wavelength shift, Δ λ (Figure 1C).

Read more

We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.